Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model
Alberto Cecconi1,2, Jean Paul Vilchez-Tschischke1,3, Jesus Mateo1
1Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
Abstract:
Colchicine demonstrated clinical benefits in the treatment of stable coronary artery disease. Our aim was to evaluate the effects of colchicine on atherosclerotic plaque stabilization. Atherosclerosis was induced in the abdominal aorta of 20 rabbits with high-cholesterol diet and balloon endothelial denudation. Rabbits were randomized to receive either colchicine or placebo. All animals underwent MRI, 18F-FDG PET/CT, optical coherence tomography (OCT), and histology. Similar progression of atherosclerotic burden was observed in the two groups as relative increase of normalized wall index (NWI). Maximum 18F-FDG standardized uptake value (meanSUVmax) decreased after colchicine treatment, while it increased in the placebo group with a trend toward significance. Animals with higher levels of cholesterol showed significant differences in favor to colchicine group, both as NWI at the end of the protocol and as relative increase in meanSUVmax. Colchicine may stabilize atherosclerotic plaque by reducing inflammatory activity and plaque burden, without altering macrophage infiltration or plaque typology.
Insights
Colchicine may stabilize atherosclerotic plaques by reducing inflammation and plaque burden. This study in rabbits suggests colchicine
Area of Science:
- Cardiovascular Research
- Inflammation Biology
- Medical Imaging
Background:
- Stable coronary artery disease (CAD) benefits from colchicine.
- Atherosclerotic plaque stabilization is a key therapeutic goal in CAD.
Purpose of the Study:
- To evaluate colchicine's effects on atherosclerotic plaque stabilization.
- To assess colchicine's impact on plaque inflammation and burden.
Main Methods:
- Atherosclerosis induced in rabbit abdominal aorta via high-cholesterol diet and balloon injury.
- Animals randomized to colchicine or placebo treatment.
- Multimodal imaging including MRI, 18F-FDG PET/CT, OCT, and histology used for assessment.
Main Results:
- No significant difference in atherosclerotic burden (normalized wall index) between groups.
- Colchicine treatment led to a decrease in maximum 18F-FDG standardized uptake value (meanSUVmax), indicating reduced inflammatory activity, while placebo showed an increase.
- Animals with higher cholesterol levels showed significant benefits with colchicine regarding plaque burden and reduced inflammatory activity.
Conclusions:
- Colchicine may stabilize atherosclerotic plaques by reducing inflammatory activity.
- The drug appears to reduce plaque burden without altering macrophage infiltration or plaque typology.
- Findings support colchicine's potential role in managing atherosclerosis.
Related Concept Videos
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis I: Introduction


